Simvastatin with or without ezetimibe in familial hypercholesterolemia.

@article{Kastelein2008SimvastatinWO,
  title={Simvastatin with or without ezetimibe in familial hypercholesterolemia.},
  author={John J. P. Kastelein and Fatima Akdim and Erik S. G. Stroes and Aeilko H. Zwinderman and Michiel L. Bots and Anton F. H. Stalenhoef and Frank L. J. Visseren and Eric J.G. Sijbrands and Mieke D. Trip and Evan A. Stein and Daniel Gaudet and Rapha{\"e}l Duivenvoorden and Enrico P. Veltri and Adrian D Marais and Eric de Groot},
  journal={The New England journal of medicine},
  year={2008},
  volume={358 14},
  pages={
          1431-43
        }
}
BACKGROUND Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode… 

Figures and Tables from this paper

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
TLDR
Formal cardiovascular outcome trials are underway and these will provide additional insights into the long-term effects of ezetimibe on clinical events as well as on atherogenic dyslipidaemia, beyond LDL cholesterol levels.
Statin/ezetimibe combination therapy: emerging evidence.
TLDR
The Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis (ARBITER 6-HALTS) study comparing niacin with ezetimibe as an add on to statin therapy showed clear superiority of the former, however, there are methodological reservations regarding both of these trials.
The ENHANCE trial: analysis and clinical significance
TLDR
Despite achieving a significant differential reduction in LDL-C, no regression in carotid intima-media thickness was observed at the end of the 2-year follow-up period and the results of the ongoing outcome trials with ezetimibe are needed to know for certain the effect of ezettimibe on clinical outcomes.
Extended-release niacin or ezetimibe and carotid intima-media thickness.
TLDR
This comparative-effectiveness trial shows that the use of extended-release niacin causes a significant regression of carotid intima-media thickness when combined with a statin and that niac in is superior to ezetimibe.
Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial.
TLDR
Combined therapy with fluvastatin 20 mg plus ezetimibe 10 mg daily resulted in a significant improvement in changes in the estimated glomerular filtration rate, and side-effect and safety profiles were similar in the two groups.
Ezetimibe therapy for dyslipidemia: an update.
TLDR
The results of the ongoing IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) which compares ezetimibe plus simVastatin with simvastatin monotherapy with regard to CVD outcomes after acute coronary syndromes should further elucidate the effect of ezETimibe on CVD events.
Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?
TLDR
Whether ezetimibe can add to the benefits of statins on atherosclerosis and cardiovascular risk reduction in relation to further LDL-C lowering and lipid-modifying properties is discussed.
Ezetimibe plus simvastatin for the treatment of hypercholesterolemia
TLDR
The controversy around the role of ezetimibe is broach, particularly in light of the results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), which is the first to demonstrate incremental cardiovascular risk reduction with the addition of eZetIMibe to simvastatin.
[Lower is better: ENHANCE affair].
TLDR
The experience of the ENHANCE trial suggests to pharmaceutical companies, researchers, clinicians, scientific companies and media a deep meditation in order to avoid in the future similar problems in the management of results of medical research.
...
...

References

SHOWING 1-10 OF 43 REFERENCES
Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.
TLDR
High-dose simvastatin therapy reduces arterial wall IMT in more than two thirds of the patients, with its largest effect on the femoral artery.
Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans
TLDR
Four weeks of simvastatin treatment improves endothelial function independently of LDL cholesterol lowering, at least in part by reducing oxidant stress.
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness
TLDR
Marked LDL reduction (<100 mg/dL) with a high-potency statin provides superior efficacy for atherosclerosis regression at 1 year, suggesting that marked LDL reduction with synthetic statins may provide enhanced reduction in clinical coronary event rates.
Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)
TLDR
This is the first randomized trial to show that a low-dose metoprolol CR/XL and fluvastatin can reduce the rate of progression of carotid IMT in clinically healthy, symptom-free subjects with carotids plaque, and suggests that &bgr;-blockers may have a favorable effect on atherosclerosis development.
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
TLDR
In patients with familial hypercholesterolemia, the use of torcetrapib withAtorva statin, as compared with atorvastatin alone, did not result in further reduction of progression of atherosclerosis, as assessed by a combined measure of carotid arterial-wall thickness, and was associated with progression of disease in the common carotids segment.
Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy
TLDR
Treatment with pravastatin reduced the development of carotid atherosclerosis among patients with coronary heart disease and a wide range of pretreatment cholesterol levels and prevented any detectable increase inCarotid wall thickening over 4 years of follow-up.
...
...